BioAffinity Technologies Secures Patent for Novel Cancer Therapy Targeting CD320 and LRP2 Receptors

On Wednesday, BioAffinity Technologies Inc. (NASDAQ:BIAF) announced that the US Patent and Trademark Office/USPTO has issued a new patent.

Keep Reading →